| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Medical and Research Services of the VA Wadstvorth Hospital Center and the Department ofMedicine, Cedars-Sinai Medical Center and UCLA School of Medicine, Los Angeles, California, Department of Medicine, University of Miami School of Medicine, Miami, Florida, and Departmentof Biochemistry, University of California, Riverside, Riverside, California
The present study was undertaken to evaluate the acute effects of 1, 25-dihydroxy-vitamin D3 (1, 25 (OH)2D3) on serum Ca, P and immunoreactive parathyroid hormone (iPTH) and urinary Ca, P, and cyclic AMP. In 8 normal subjects, samples were collected over intervals of 30 to 60 min during a control day and on a treatment day following oral ingestion of 1, 25(OH)2D3, 2.7 µg. For the entire group there were no significant changes in serum Ca, P, iPTH or urinary P. Urinary Ca increased significantly 7 h after administration of 1, 25(OH)2D3, and urinary cAMP decreased at 12 h. In 4 patients (group A), showing an increase in serum Ca by 0.2 to 0.4 mg/dl, serum iPTH decreased in 3, and the decrease in urinary cAMP appeared sooner. Among 4 patients showing no change in serum Ca after 1, 25(OH)2D3 (group B), 3 showed an increase in iPTH. These data document the early onset of action of 1, 25(OH)2D3 following its administration to normal man;increments in urinary Ca provide the most sensitive index of its action. The data provide no support for the view that 1, 25(OH)2D3 exerts any direct inhibitory effect on the secretion of parathyroid hormone.
1 Clinical Investigator of the Veterans Administration.
2 Present address: Division of Nephrology, Los Angeles County-University of Southern California Medical Center, Los Angeles, California.
Supported in part by NIH grants AM-14750, AM-5383 and AM-16768, and by research funds from the Veterans Administration.
Received June 14, 1976.
This article has been cited by other articles:
![]() |
L. Brandi, M. Egfjord, and K. Olgaard Pharmacokinetics of 1,25(OH)2D3 and 1{alpha}(OH)D3 in normal and uraemic men Nephrol. Dial. Transplant., May 1, 2002; 17(5): 829 - 842. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. L. Voigts, A. J. Felsenfeld, and F. Llach The Effects of Calciferol and Its Metabolites on Patients With Chronic Renal Failure: II. Calcitriol, 1{alpha}-Hydroxyvitamin D3, and 24,25-Dihydroxyvitamin D3 Arch Intern Med, June 1, 1983; 143(6): 1205 - 1211. [Abstract] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |